NCT02625792View on ClinicalTrials.gov

Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Iatrogenic Ulcer After ESD
Interventions
DRUG

Endo-Clot(TM)

After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.

Trial Locations (1)

03722

Yonsei university of medical center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02625792 - Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD | Biotech Hunter | Biotech Hunter